secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001628280-26-010186
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Kaitlyn Arsenault to step down Feb 20; CEO Punit Dhillon appointed principal accounting officer
--------------------------------------------------------------------------------

- CFO Kaitlyn Arsenault departs Feb 20, 2026; no disagreement with auditors or company on financials.
- Severance: $450,000 cash, $45,000 annual bonus, up to $30,000 legal fees, $41,172 COBRA reimbursement.
- Arsenault will serve as advisor for 6 months; outstanding equity awards continue vesting.
- CEO Punit Dhillon appointed principal accounting officer effective Feb 20; remains CEO and President.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026010186/0001628280-26-010186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026010186/skye_021826x8kkmaseparation.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-010186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer